selective lymph node dissection

PROCEDURE3 trials

Sponsors

Shanghai Zhongshan Hospital, Fudan University

Conditions

Lung AdenocarcinomaLung Cancer (NSCLC)Lymph Node DissectionLymph Node MetastasisPostoperative RecoveryProgression

Phase 3

Selective Lymph Node Dissection for cT1N0M0 Invasive NSCLC With CTR>0.5 Located in the Apical Segment (ECTOP-1018)

RecruitingNCT06031246

Fudan UniversityLung Adenocarcinoma, Lymph Node Metastasis

Start: 2023-04-01End: 2030-12-31Target: 634Updated: 2023-09-11

Unknown Phase

A Single-center Study on the Effect of Systemic/Selective Lymph Node Dissection on the Prognosis of Ground Glass Nodules Smaller Than 3cm and With Components With Consolidation/Tumor Ratio Between 0.5-1

Not yet recruitingNCT05184829

Shanghai Zhongshan HospitalPostoperative Recovery, Progression

Start: 2022-01-01End: 2029-12-31Target: 500Updated: 2022-01-11

Selective Lymph Node Resection for Invasive Non-small Cell Lung Cancer With the CTR of 0.5-1 and the Diameter of ≤ 2 cm

RecruitingNCT06634979

Fudan UniversityLung Cancer (NSCLC), Lymph Node Dissection

Start: 2024-05-01End: 2029-05-01Target: 684Updated: 2025-08-12

Related Papers

Protocol of a single-arm, multicenter, phase III trial for selective lymph node dissection in cT1N0M0 invasive non-small cell lung cancer with consolidation-tumor ratio >0.5 located in the apical segment: Eastern Cooperative Thoracic Oncology Projects ECTOP-1018 (SELLAS study)

Journal of Thoracic Disease2024-11-01